Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Soleus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(197)
•••
Comment by scarlet1967on Nov 28, 2023 7:37pm
96 Views
Post# 35757582

RE:RE:RE:RE:RE:RE:Soleus

RE:RE:RE:RE:RE:RE:Soleus

Thanks for clarification. 



palinc2000 wrote: The 9 325 511 shares were solit spit into 2 331 3317 shares after the consolidation and they purchased over 2,5 million shares from the Offeing ,,,Had they not bought additional shares their holding would have been reduced to 5 per cent or so

scarlet1967 wrote:
scarlet1967 wrote: Do the math, 10percent before dilation and 10 percent after 

On November 14, 2023 - Soleus Capital Management, L.P. filed a 13F-HR form disclosing ownership of 0 shares of Theratechnologies Inc (CA:TH) valued at USD as of September 30, 2023. The entity filed a previous 13F-HR on August 14, 2023 disclosing 9,325,511 shares of Theratechnologies Inc. This represents a change in shares of -100.00% during the quarter. The current value of the position is USD.
This is from Fintel if correct they did offload shares and bought back. As for precentage it is irrelevant they sold and bought back 




 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities